BRIACELL THERAP (BCTX) vs 4D pharma PLC Sponsored ADR (LBPS)

BRIACELL THERAP and 4D pharma PLC Sponsored ADR are both Biotechnology companies. BRIACELL THERAP and 4D pharma PLC Sponsored ADR are of similar size ($37.2M and $37.2M). 4D pharma PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; BRIACELL THERAP trades at 1.9×. BRIACELL THERAP has the higher net margin (0.00% vs −9,577.1%) and the lower return on invested capital (−3,311.0% vs 0.00%). Across the 12 metrics below, BRIACELL THERAP leads on 8 and 4D pharma PLC Sponsored ADR on 4.

Valuation

Metric BCTX LBPS Biotechnology median
P/E 1.94 n/m 7.88
P/S n/m 211.23 11.47
P/B 1.34 9.49 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 205.89 10.73
Earnings yield 51.65% (40.76%) (28.84%)
Free cash flow yield (100.28%) (30.32%) (23.03%)

Profitability

Metric BCTX LBPS Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (9,577.06%) 0.00%
Free cash flow margin 0.00% (6,318.73%) 0.00%
Return on equity (173.55%) (742.15%) (57.72%)
Return on assets (139.20%) (371.23%) (49.22%)
Return on invested capital (3,311.00%) 0.00% 0.00%

Growth

Metric BCTX LBPS Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (43.04%) 35.04% —
Revenue growth, 5-year CAGR — 21.70% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCTX LBPS Biotechnology median
Debt to equity 0.00 0.43 0.00
Current ratio 7.07 5.21 4.73
Net debt to EBITDA 0.66 0.23 0.96

Dividend

Metric BCTX LBPS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BCTX LBPS Biotechnology median
Market cap 37.24m 37.19m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack